Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

April 13, 2018: By Jon Swedien

AbbVie has struck a deal with Samsung Bioepis and Biogen that will allow the partners to sell Imraldi—a biosimilar referencing Humira (adalimumab)—in Europe beginning in 2018, and, in exchange, they have agreed to drop a lawsuit challenging Humira’s patent, the companies announced April 5.

Humira is indicated in Europe for chronic non-infectious anterior uveitis.

Under terms of the agreement, AbbVie said it will grant patent licenses for the use and sale of Imraldi in Europe on a country-by-country basis, and the license period will begin in most European Union countries Oct. 16, 2018.

Samsung Bioepis and Biogen will make royalty payments to AbbVie, the companies said.

AbbVie also disclosed the deal will allow Samsung Bioepis to sell its biosimilar in the US beginning June 30, 2023.

The precise terms of the agreements are confidential, the companies said.

In 2017, AbbVie struck a deal with Amgen allowing it to sell its Humira biosimilar in the US beginning in January 2023 in exchange for royalty payments to AbbVie and dropping a patent challenge to Humira.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT